Reata Pharmaceuticals, Inc.

John Allen Walling

Stephan D Parent

David T Jonaitis

Robert M Kral, Jr

Xin Jiang

Melanie Janelle Bevill

Jared Peters Smit

Christopher Scott Seadeek

Christopher S Seadeek

Melanie J Bevill

Jared P Smit

Disclosed are co-crystal forms of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,1&#x2032;-biphenyl]-2-yl)ethyl)-acetamide and L-proline or D-proline, their pharmaceutical compositions, processes of manufacture, and methods of use for treating neurodegenerative disorders such as diabetic peripheral neuropathy.

Co-crystal forms of a novobiocin analog and proline

A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

Forms of CDDO methyl ester

Growing community of inventors

Cisco, TX, United States of America

John Allen Walling